Langrand-Escure J, de Crevoisier R, Llagostera C, Créhange G, Delaroche G, Lafond C, Bonin C, Bideault F, Sargos P, Belhomme S, Pasquier D, Latorzeff I, Supiot S, Hennequin C
Institut de cancérologie de La-Loire-Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France.
Département de radiothérapie, centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35042 Rennes, France; Inserm 1099, laboratoire traitement du signal et de l'image (LTSI), 263, avenue du Général-Leclerc, 35042 Rennes, France.
Cancer Radiother. 2018 Apr;22(2):193-198. doi: 10.1016/j.canrad.2017.11.004. Epub 2018 Apr 5.
Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques.
考虑到近期的III期试验结果，中度分割放疗可被视为低危和中危前列腺癌治疗的标准方法。这一评估需要一个框架，以便在使用这种放疗方案的不同中心实现同质化和可重复的操作。法国泌尿生殖组（GETUG）在此提供了前列腺癌中度分割放疗的日常实践建议，包括适应证、剂量、分割方式、治疗前规划、靶区勾画（靶体积和危及器官）及边界、剂量限制和放疗技术。
